公司资料

89bio, Inc. 股价、新闻与催化剂

股票代码:: ETNB
交易所:: NASDAQ
行业:: Biopharma
所在地:: United States

股价为何变动

Current closing-price context is not available for ETNB.

公司概览

业务概览

89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.

所在地与行业分类

Headquartered in the United States and listed on NASDAQ, 89bio sits in specialty biopharma.

商业模式特征

The business depends on clinical data, dose strategy, and whether the company can deliver a differentiated MASH profile.

生物医药行业定位

89bio is one of the more closely watched liver-disease names because efficacy and safety can quickly change the story.

未来催化剂

89bio's catalysts are pegozafermin in MASH and severe hypertriglyceridemia, where the next data step can materially change the valuation. The company is still being judged on metabolic-disease execution.